A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Full story
Read the full story at CNBC ↗
Continue reading this story on CNBC, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
